PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION

Mr. Mohan Kumar . -- SAMPLE TYPE :Serum

ASK TECHSOFT LLP ( DR SAFE HANS.COM ) ORDER REQ. NO :OREQ-AMP-18-1108355
AGE : 30Y LAB ORDER. NO :1811778701
GENDER : Male Lab MR #: 1679621 COLLECTED ON :17-Sep-2018 11:00
PRIORITY : Routine RECEIVED ON :18-Sep-2018 16:48
OP / IP / DG # : REPORT STATUS :Completed

SEROLOGY & IMMUNOLOGY

Test Name (Methodology) Result Flag Units Biological Reference
Interval

HIV I & II Antibody reflex to P24 Antigen capture *

HIV p24 Antigen (Screen ) * (ELFA) Not detected
Observations:

HIV 1+2 is a screening test. A non-reactive test does not exclude the possibility of an HIV infection. HIV 1+2 detects only anti-HIV antibodies. The
assay is only valid for human serum and Plasma samples and not for other body fluids. All Reactive specimens must be further confirmed using
other tests such as Western Blot and PCR.

This test has been performed after providing pre-test counselling to the patient and obtaining informed consent.
This test result will be handed over to the patient after post test counselling and due clinical interpretation by a registered medical practitioner.

Biological Reference Interval for HIV p24:

<0.25 : Not Detected
>0.25 : Detected

Test Description :
The HIV Ag/Ab Combo(HIV DUO) assay is a Screening test for simultaneous qualitative detection of
HIV p24 antigen and antibodies to HIV type 1 and/or 2 in human serum or plasma. However, the HIV Ag/Ab Combo
result does not distinguish between the detection of HIV p24 antigen, HIV-1 antibody, or HIV-2 antibody separately.

Test Interpretation :
• Non Reactive results may not rule-out acute or early HIV infection in the window period. If acute HIV-1 infection
is suspected, detection of HIV-1 RNA or HIV proviral is recommended.
• Reactive results suggest possibility of preliminary infection with HIV-1 and/or HIV-2. All reactive samples should
be verified by submitting a second serum specimen for repeat testing with screening & supplemental or
confirmatory HIV tests (by serology-HIV 1 & 2 western blot or molecular- HIV 1 & 2 PCR).
• For the received samples, it is presumed that patient counselling is done at referring centre or by referring
physician.

This test has been performed after providing pre-test counselling to the patient and obtaining informed consent.
This test result will be handed over to the patient after post test counselling and due clinical interpretation by a registered medical practitioner.

HIV I & II Antibody * (ELISA) 0.04 Index Value <1.00 : Non-reactive

>=1.00 : Reactive
Syphilis/ Treponemal Antibody * (ELISA) 0.21 INDEX Negative: <1.0, Positive:
>=1.0
Generated On 20-Sep-2018 13:24:07 670.8 This is an electronically authenticated laboratory report. Page 1 of 3
 PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION
Mr. Mohan Kumar . -- SAMPLE TYPE :Serum
ASK TECHSOFT LLP ( DR SAFE HANS.COM ) ORDER REQ. NO :OREQ-AMP-18-1108355
AGE : 30Y LAB ORDER. NO :1811778701
GENDER : Male Lab MR #: 1679621 COLLECTED ON :17-Sep-2018 11:00
PRIORITY : Routine RECEIVED ON :18-Sep-2018 16:48
OP / IP / DG # : REPORT STATUS :Completed

SEROLOGY & IMMUNOLOGY

Test Name (Methodology) Result Flag Units Biological Reference
Interval

Test Observations:
This is a qualitative test which detects the presence of antibodies to Treponema pallidum (TP). In case results are inconsistent with clinical
evidence, additional testing is suggested to confirm the result. No diagnostic test provides absolute assurance that a sample does not contain low
levels of antibodies to TP, such as those present at a very early stage of infection. Therefore, a negative result at any time does not preclude the
possibility of exposure to infection with syphilis. Additional information may be required for diagnosis.

Chlamydia Trachomatis IgG Antibodies *

Chlamydia Trachomatis IgG Antibody * 0.10 Index NEGATIVE: < 0.8
BORDERLINE: 0.8-1.1
POSITIVE: > 1.1

Chlamydia Trachomatis IgM Antibodies * 0.41 Ratio Negative: < 0.8

Borderline: 0.8-1.1
Positive: > 1.1
Hepatitis B surface antigen (HBsAg) - Screening
Hepatitis B surface antigen (CLIA) 0.13 Index Value <1.00 : Non-reactive
>=1.00 : Reactive

Test Observations:
HBsAg is the first marker to appear after Hepatitis B infection and may be observed 2 or 3 weeks before the clinical and biological symptoms of
the disease appear. Its period of presence may be very short (a few days) or very long (several years). HBs Ag persisting beyond 6 months in the
serum denotes "chronic hepatitis".Because of the existence of numerous asymptomatic chronic carriers, hepatitis B represents an important
transfusion hazard and the prevention of the transmission is based upon the detection of the HBs Ag at the time of each blood donation. This is a
screening test and all positive samples must be confirmed by confirmatory tests like Neutralization assay or PCR.
False positive results can be obtained due to the presence of other antigens or elevated levels of Rheumatoid factor (RF), although this is seen in
less than 1% of the samples tested.

Hepatitis C Virus (HCV) Antibody (CLIA) 0.07 Index Value <1.00 : Non-reactive
>=1.00 : Reactive
Test Observations:

This is a fourth generation HCV test that pertains to qualitative detection of antibodies against Hepatitis C Virus in patient serum/ plasma it is used
for screening of infected blood samples.
The 4th generation HCV test utilizes a unique combination of modified HCV antigens from the putative core, NS3, NS4 and NS5 regions of the
virus to selectively identify all subtypes of Hepatitis C Virus in human serum/plasma with a high degree of sensitivity and specificity. This is only a
screening test and all reactive samples should be further confirmed by supplemental assays like RIBA or Qualitative PCR. A non-reactive test does
not exclude the possibility of HCV infection. This test detects only IgG antibody against HCV.

Treponema Pallidum Haemagglutination Assay (TPHA)

Treponema Pallidum Haemagglutination Assay Negative Negative
(Haemagglutination)
Generated On 20-Sep-2018 13:24:07 670.8 This is an electronically authenticated laboratory report. Page 2 of 3
 PATIENT INFORMATION REFERRED BY SPECIMEN INFORMATION
Mr. Mohan Kumar . -- SAMPLE TYPE :Serum
ASK TECHSOFT LLP ( DR SAFE HANS.COM ) ORDER REQ. NO :OREQ-AMP-18-1108355
AGE : 30Y LAB ORDER. NO :1811778701
GENDER : Male Lab MR #: 1679621 COLLECTED ON :17-Sep-2018 11:00
PRIORITY : Routine RECEIVED ON :18-Sep-2018 16:48
OP / IP / DG # : REPORT STATUS :Completed

SEROLOGY & IMMUNOLOGY

Test Name (Methodology) Result Flag Units Biological Reference
Interval

Test Observations:
No serological Haemagglutination test can discriminate between antibody due to T.pallidum infection and antibody due to infection with other
pathogenic treponems. No other interfering factors have been specifically identified however positive results should be confirmed by FTA-Abs, and
complemented by clinical findings.

Herpes Simplex Virus 1 IgM - Serum

Herpes Simplex Virus 1 IgM (ELISA) (ELISA) 0.23 Ratio < 0.8 : Negative
0.8 – 1.1 : Borderline
> 1.2 : Positive
Herpes Simplex Virus 2 IgG - Serum
Herpes Simplex Virus 2 IgG (ELISA) 0.07 Ratio < 0.8 : Negative
0.8 – 1.1 : Borderline
> 1.2 : Positive
Herpes Simplex Virus 2 IgM - Serum
Herpes Simplex Virus 2 IgM (ELISA) (ELISA) 0.39 Ratio < 0.8 : Negative
0.8 – 1.1 : Borderline
> 1.2 : Positive

Test Observations:

The TORCH panel screens for Toxoplasma gondii, Rubella virus, Cytomegalo virus, Herpes simplex virus can be transmitted from the mother to the
foetus causing serious congenital infections. Hence pregnant women or those planning pregnancy are screened for their antibody status and
accordingly monitored during the course of their pregnancy. The test is also used to screen neonates for suspected congenital infection.
IgG TORCH ntibodies usually represent past infection whereas IgM antibodies are seen in Acute phase of a primary infection.

Herpes Simplex Virus 1 IgG - Serum

Herpes Simplex Virus 1 IgG (ELISA) 0.11 Ratio < 0.8 : Negative
0.8 – 1.2 : Borderline
> 1.2 : Positive

Authorized by Dr. Haroon Hussain Syed

Checked by Mr. Sai Praneeth Alapati Consultant - Microbiology
Sr. Technologist 20-Sep-2018 13:23
-----End of Report-----
Tests marked with (*) are not included in the scope of NABL accreditation

Generated On 20-Sep-2018 13:24:07 670.8 This is an electronically authenticated laboratory report. Page 3 of 3